Latest Sales Performance News

Bubs Australia reported a 30% increase in net revenue to $25.6 million for Q1 FY26, driven by robust US sales and a return to profitability with positive EBITDA. Despite inventory challenges in other regions, the company maintains a solid cash position and anticipates FDA approval by year-end.

Urbanise.com Limited reported a 12.4% revenue increase in Q1 FY2026, driven by its NAB partnership, while investing heavily in its Data and Payments Integration Services (DPIS) with expected cash outflows through FY2026.

JB Hi-Fi reports solid Q1 FY26 sales growth, led by a remarkable 39.3% increase in New Zealand, while Australian sales maintain steady momentum. The Good Guys and e&s show modest gains as the group prepares for a critical Q2.

Next Science reported a 3% rise in Q3 product sales and completed a $50 million asset sale to OSARTIS GmbH, setting the stage for a significant shareholder return.

MyEco Group reported a modest 2% sales increase in Q1 FY26, driven by strong council channel growth that offsets U.S. tariff-related setbacks. Operational restructuring and regulatory tailwinds underpin its medium-term outlook.

Range International Limited has reported its strongest quarterly sales to date, driven by its Re>Pal Indonesia operations, while gearing up to double production capacity with a new factory and pivoting to a pallet rental model.

Super Retail Group reports steady sales growth across its brands in the first 16 weeks of FY26, with Macpac leading the charge and a new loyalty program launched at Supercheap Auto.

Saferoads Holdings Limited reported a solid quarterly profit of $346,000, driven by strong product sales including a key order from On-site Rentals. However, the company signals caution on sustaining profitability due to market uncertainties and inventory adjustments.

PainChek Limited has confirmed FDA De Novo classification for its PainChek Adult App, promptly disclosing the material regulatory milestone to the ASX and signalling a significant step towards US market entry.

Telix Pharmaceuticals reports a robust 53% revenue jump in Q3 2025 and raises its full-year guidance, underpinned by key reimbursement wins and expanding clinical programs.

New Murchison Gold Limited has reported a robust start to production at its Crown Prince Gold Mine, with significant ore processed and first revenue expected in October 2025.

Synlait Milk Limited reported an 11.7% rise in revenue to NZD 1.83 billion for the year ending July 2025, yet its net loss deepened sharply to nearly NZD 40 million, prompting a halt on dividends.